

A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Study to Investigate the Safety and Efficacy of Oral Brepocitinib in Adults with Cutaneous or Oral Lichen Planus or Lichen Planopilaris

Status: Recruiting

Eligibility Criteria

Sex: Male or Female

Age Group: 18 years and over

This study is NOT accepting healthy volunteers

Inclusion Criteria:

- diagnosed with lichen planopilaris (LPP)

Exclusion Criteria:

- have a history of certain blood or lymphatic system cancers, currently have cancer, or have been treated for most cancers within the past 5 years - have a high risk of blood clots, heart disease, stroke, or shingles

Conditions & Interventions

Interventions:

Drug: Oral Brepocitinib, Drug: Placebo

Conditions:

Dermatology (Skin, Hair & Nails)

Keywords:

Clinics and Surgery Center (CSC), lichen planopilaris, LPP

More Information

Description: The purpose of this study is to learn more about the use of an investigational medicine, called brepocitinib, for the treatment of lichen planopilaris (LPP). Brepocitinib (the "study drug") is designed to decrease inflammation. The study will look at how safe and effective brepocitinib is and will monitor long-term safety when it is taken for up to 52 weeks. The study drug will be compared to a placebo which is a tablet that looks exactly like the study drug but does not contain any active ingredient.

Study Contact: Jaime Nugent - speck007@umn.edu

Principal Investigator: Maria Hordinsky

Phase: PHASE2

IRB Number: STUDY00027335

Thank you for choosing StudyFinder. Please visit <http://studyfinder.umn.edu> to find a Study which is right for you and contact sfinder@umn.edu if you have questions or need assistance.